

4A (medical oncologist) ...We would advise them to have their ovaries removed now ... we are quite directive, in regards to ovaries, we think this is the best option ... if the women prefers not to have the BSO and it's very unusual ... we would then advise screening, on the understanding that we've no proof of its benefits ... And then in terms of her breasts we'd be canvassing her thoughts on whether she's ever considered risk reducing mastectomy... at the current time we don't mention Tamoxifen as a prevention agent, um, mainly because it's um--well we will, once we've got IBIS 2 up and running. So we will be involved in a clinical trial. It's not licensed for use in the prevention context, and obviously there are side effects.